Ocugen, Inc.
(NASDAQ : OCGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.63%62.610.0%$958.21m
NVAXNovavax, Inc. -2.02%94.36251.8%$764.51m
AMGNAmgen, Inc. -1.04%249.041.3%$693.79m
REGNRegeneron Pharmaceuticals, Inc. -3.09%620.862.5%$663.02m
GILDGilead Sciences, Inc. 2.16%76.321.0%$630.80m
BIIBBiogen, Inc. 0.07%278.881.6%$601.57m
VRTXVertex Pharmaceuticals, Inc. -0.32%294.451.9%$475.52m
ILMNIllumina, Inc. -0.63%370.253.5%$301.18m
VXRTVaxart, Inc. -2.56%7.980.0%$286.91m
ALXNAlexion Pharmaceuticals, Inc. 0.32%108.822.0%$217.19m
BMRNBioMarin Pharmaceutical, Inc. -0.59%126.064.3%$206.81m
SRNESorrento Therapeutics, Inc. 4.00%8.061.8%$192.86m
SGENSeattle Genetics, Inc. -3.76%174.356.1%$192.39m
IMMUImmunomedics, Inc. -2.32%41.3211.0%$177.00m
ALNYAlnylam Pharmaceuticals, Inc. 2.03%162.258.5%$166.65m

Company Profile

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.